Volume 26, Issue 4 e14238
ORIGINAL ARTICLE

Nondestructive versus advanced post-transplant lymphoproliferative disorder in a single-center pediatric kidney transplant population

Ellen Wu

Ellen Wu

Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Search for more papers by this author
Joo-Young Lee

Joo-Young Lee

Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Search for more papers by this author
Ian Gelarden

Ian Gelarden

Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Search for more papers by this author
Rachel M Engen

Corresponding Author

Rachel M Engen

Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Correspondence

Rachel M Engen, Department of Pediatrics, 1675 Highland Ave, Madison, WI 53792, USA.

Email: [email protected]

Search for more papers by this author
First published: 30 January 2022
Citations: 1

Funding information

The authors have no funding sources to disclose

Abstract

Background

Pediatric kidney transplant recipients are at risk for the development of post-transplant lymphoproliferative disorders (PTLD), a group of potentially devastating diseases that present on a spectrum of severity ranging from nondestructive PTLD to more histologically destructive lesions. Currently, there is inadequate evidence to guide evaluation and management of nondestructive PTLD.

Methods

This is a single-center case series of pediatric kidney transplant recipients between January 1, 2008 and December 31, 2019, who were diagnosed with PTLD. The aim was to describe clinical characteristics, presentation, and management of nondestructive versus advanced PTLD.

Results

Eighteen patients were diagnosed with nondestructive PTLD and seven with more advanced PTLD histopathology. The majority (66.7%) of nondestructive PTLD patients (n = 16) presented with tonsillar hypertrophy and/or snoring and were managed conservatively, with minimal reduction in tacrolimus dose and no further evaluation. No patient progressed to more advanced PTLD. Advanced PTLD patients (n = 7) were more likely to present with fever, elevated creatinine, a new mass of gastrointestinal symptoms. They received workup with imaging and oncology consultation, and were managed with chemotherapy.

Conclusions

Patients with nondestructive PTLD often present with symptoms of sleep-disordered breathing and can be managed conservatively with excellent clinical outcomes. More study is needed to guide care of this under-researched population.

CONFLICT OF INTEREST

The authors have no conflict of interest to disclose.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.